πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 373 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10947216

Amide compounds and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941140

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941135

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941134

AMPK-activating heterocyclic compounds and methods for using the same

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10889562

Prodrugs of Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10858335

2,3-Disubstituted pyridine compounds as TGF-Ξ² inhibitors and methods of use

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851093

Tyrosine kinase inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10844040

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10828301

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822337

TGF-Ξ² inhibitorC

Rigel Pharmaceuticals, Inc. Β· Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10815206

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10792282

Protein kinase C inhibitors and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10774076

Benzazole compounds and methods for making and using the compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10774066

Prodrugs of NRF2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10759855

Antigen binding molecules to TIGIT

Rigel Pharmaceuticals, Inc. Β· Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10710983

2,4-diamino-pyrimidine compounds and method for making and using the compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10709703

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10696693

Fused imidazole derivatives as TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10682350

2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10647697

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10590121

Kinase inhibitors and methods for making and using

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10577381

Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10556881

Nrf2 activating compounds and uses thereof

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10556891

Compositions and methods for inhibition of the JAK pathway

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted